•
Sep 30, 2022
Rigel Q3 2022 Earnings Report
Rigel reported a net loss for the third quarter of 2022, but saw increased TAVALISSE sales.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $19.0 million for the third quarter of 2022. Total revenues were $22.4 million, including $19.2 million in TAVALISSE net product sales, which increased by 20% compared to the same period in 2021.
Net loss of $19.0 million, or $0.11 per basic and diluted share.
Total revenues were $22.4 million.
TAVALISSE net product sales increased by 20% to $19.2 million.
Made progress to position the company for the potential launch of olutasidenib and to drive growth in TAVALISSE ITP sales.